Multiorgan repair by MSC-derived extracellular vesicles in hepatorenal syndrome through necroptosis alleviation, immune reprogramming and fibrosis resolution

Abstract

Aim: To investigate the therapeutic potential and underlying mechanism of mesenchymal stem cell (MSC)-derived extracellular vesicles (MSC-EVs) in treating hepatorenal syndrome (HRS), a condition lacking therapies for multi-organ damage.

Methods: EVs were isolated from human umbilical cord MSCs and characterized by transmission electron microscopy, nanoparticle tracking analysis, and proteomics. A murine model of HRS, induced by bile duct ligation (BDL), was established, and mice received intravenous MSC-EVs treatment. Therapeutic efficacy was assessed through histopathology, serum biochemistry, and analysis of necroptosis, inflammation, and fibrosis markers.

Results: Proteomic profiling of MSC-EVs revealed significant enrichment of proteins involved in renal processes, anti-fibrosis, and immune regulation. In BDL-induced HRS mice, MSC-EVs treatment demonstrated potent multi-organ protective effects. This was evidenced by alleviation of hepatic necroptosis and renal tubular injury, downregulation of interleukin-17 expression, and concurrent attenuation of fibrosis in both liver and kidney tissues. Consequently, significant improvements in hepatic and renal function markers were observed.

Conclusion: MSC-EVs represent a novel and effective cell-free nanotherapeutic strategy for HRS. They confer protection through multi-faceted mechanisms, including inhibition of necroptosis, immune reprogramming, and fibrosis resolution, offering a promising paradigm for the treatment of multi-organ failure.

Keywords

Mesenchymal stem cell / extracellular vesicles / hepatorenal syndrome / necroptosis / immune modulation / fibrosis

References

[1] Pose E,Juanola A.Hepatorenal syndrome in cirrhosis.Gastroenterology2024;166:588-604.e1

[2] Simonetto DA,Kamath PS.Hepatorenal syndrome: pathophysiology, diagnosis, and management.BMJ2020;370:m2687

[3] Ginès P,Angeli P,Nadim MK.Hepatorenal syndrome.Nat Rev Dis Primers2018;4:23

[4] Angeli P,Wong F.Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Club of Ascites.J Hepatol2015;62:968-74

[5] Belcher JM.Hepatorenal syndrome: pathophysiology, diagnosis, and treatment.Med Clin North Am2023;107:781-92

[6] Gaytan SL,Gadad SS.Progress and prospect of nanotechnology for cardiac fibrosis treatment.Interdiscip Med2023;1:e20230018 PMCID:PMC10712437

[7] Solé C,Huelin P.Characterization of inflammatory response in hepatorenal syndrome: relationship with kidney outcome and survival.Liver Int2019;39:1246-55 PMCID:PMC6767546

[8] Albillos A,Álvarez-Mon M.Cirrhosis-associated immune dysfunction: distinctive features and clinical relevance.J Hepatol2014;61:1385-96

[9] Dai H,Wang C.Recent applications of immunomodulatory biomaterials for disease immunotherapy.Exploration2022;2:20210157 PMCID:PMC10191059

[10] Sun S,Cai Y.A single-cell transcriptomic atlas of exercise-induced anti-inflammatory and geroprotective effects across the body.Innovation2023;4:100380 PMCID:PMC9898793

[11] Xu L,Fang X.Exploring precision treatments in immune-mediated inflammatory diseases: harnessing the infinite potential of nucleic acid delivery.Exploration2025;5:20230165 PMCID:PMC11875455

[12] Bernardi M,Angeli P,Arroyo V.Mechanisms of decompensation and organ failure in cirrhosis: from peripheral arterial vasodilation to systemic inflammation hypothesis.J Hepatol2015;63:1272-84

[13] Albillos A,Van der Merwe S,Jalan R.Cirrhosis-associated immune dysfunction.Nat Rev Gastroenterol Hepatol2022;19:112-34

[14] Song N,Shah K.Mesenchymal stem cell immunomodulation: mechanisms and therapeutic potential.Trends Pharmacol Sci2020;41:653-64 PMCID:PMC7751844

[15] Shareghi-Oskoue O,Yousefi M.Transplantation of human umbilical cord mesenchymal stem cells to treat premature ovarian failure.Stem Cell Res Ther2021;12:454 PMCID:PMC8359553

[16] Regmi S,Kim JO,Jeong JH.Mesenchymal stem cell therapy for the treatment of inflammatory diseases: challenges, opportunities, and future perspectives.Eur J Cell Biol2019;98:151041

[17] Lotfy A,Wang H.Mesenchymal stromal/stem cell (MSC)-derived exosomes in clinical trials.Stem Cell Res Ther2023;14:66 PMCID:PMC10079493

[18] Kalluri R.The biology, function, and biomedical applications of exosomes.Science2020;367:eaau6977 PMCID:PMC7717626

[19] Mizenko RR,Bozkurt BT.A critical systematic review of extracellular vesicle clinical trials.J Extracell Vesicles2024;13:e12510 PMCID:PMC11428870

[20] Brigstock DR.Extracellular vesicles in organ fibrosis: mechanisms, therapies, and diagnostics.Cells2021;10:1596 PMCID:PMC8305303

[21] Huang Y,Russell AE.Toward a human brain extracellular vesicle atlas: characteristics of extracellular vesicles from different brain regions, including small RNA and protein profiles.Interdiscip Med2023;1:e20230016

[22] Chiabotto G,Ceccotti E.Extracellular vesicles: emerging therapeutic agents for liver fibrosis.Extracell Vesicles Circ Nucl Acids2025;6:216-44 PMCID:PMC12367467

[23] Mincheva G,Felipo V.Extracellular vesicles from mesenchymal stem cells improve neuroinflammation and neurotransmission in hippocampus and cognitive impairment in rats with mild liver damage and minimal hepatic encephalopathy.Stem Cell Res Ther2024;15:472 PMCID:PMC11656658

[24] Li R,Chen X.Phosphatidylserine-mediated uptake of extracellular vesicles by hepatocytes ameliorates liver ischemia-reperfusion injury.Apoptosis2025;30:69-82

[25] Miao L,Guan G.Extracellular vesicles containing GAS6 protect the liver from ischemia-reperfusion injury by enhancing macrophage efferocytosis via MerTK-ERK-COX2 signaling.Cell Death Discov2024;10:401 PMCID:PMC11387478

[26] Zhang X,Zhang S.Mesenchymal stem cell-derived extracellular vesicles for human diseases.Extracell Vesicles Circ Nucl Acids2024;5:64-82 PMCID:PMC11648454

[27] Li B,Zhang Y.Frontier role of extracellular vesicles in kidney disease.J Nanobiotechnology2024;22:583 PMCID:PMC11414213

[28] Kosanović M,Kutzner TJ,Bozic M.Clinical prospect of mesenchymal stromal/stem cell-derived extracellular vesicles in kidney disease: challenges and the way forward.Pharmaceutics2023;15:1911 PMCID:PMC10384614

[29] Ji C,Shi H.Single-cell RNA transcriptomic reveal the mechanism of MSC derived small extracellular vesicles against DKD fibrosis.J Nanobiotechnology2024;22:339 PMCID:PMC11184851

[30] Pan L,Font-Morón M.Beyond preclinical promise: can mesenchymal stromal cell-derived extracellular vesicles reliably target tubular epithelial cells?.Extracell Vesicles Circ Nucl Acids2025;6:580-93 PMCID:PMC12540260

[31] Wu T,Wang S.MSC-derived extracellular vesicles: roles and molecular mechanisms for tissue repair.Int J Nanomedicine2025;20:7953-74 PMCID:PMC12191179

[32] Ceccotti E,Herrera Sanchez MB.Naïve or engineered extracellular vesicles from different cell sources: therapeutic tools for kidney diseases.Pharmaceutics2023;15:1715 PMCID:PMC10303377

[33] Liu L,Zhao N.Mesenchymal stem cell aggregation-released extracellular vesicles induce CD31⁺ EMCN⁺ vessels in skin regeneration and improve diabetic wound healing.Adv Healthc Mater2023;12:e2300019

[34] Yang J,Jiang S.Engineered brain-targeting exosome for reprogramming immunosuppressive microenvironment of glioblastoma.Exploration2025;5:20240039 PMCID:PMC12087404

[35] Yang J,He M.Engineered exosome-based senolytic therapy alleviates stroke by targeting p21⁺CD86⁺ microglia.Exploration2025;5:20240349

[36] Zheng C,Zhang X.Apoptotic vesicles restore liver macrophage homeostasis to counteract type 2 diabetes.J Extracell Vesicles2021;10:e12109 PMCID:PMC8144839

[37] Krones E,Pollheimer MJ.NorUrsodeoxycholic acid ameliorates cholemic nephropathy in bile duct ligated mice.J Hepatol2017;67:110-9

[38] Li YY,Lu JW.Lysosome-featured cell aggregate-released extracellular vesicles regulate iron homeostasis and alleviate post-irradiation endothelial ferroptosis for mandibular regeneration.Adv Sci2025;12:e05070

[39] Ommati MM,Mousavi K.Metformin alleviates cholestasis-associated nephropathy through regulating oxidative stress and mitochondrial function.Liver Res2021;5:171-80 PMCID:PMC11791814

[40] Zhang S,Zheng CX.D-mannose alleviates type 2 diabetes and rescues multi-organ deteriorations by controlling release of pathological extracellular vesicles.Exploration2025;5:20240133 PMCID:PMC12561340

[41] Shao M,Sun J.Saikosaponin b1 attenuates liver fibrosis by blocking STAT3/Gli1 interaction and inducing gli1 degradation.Exploration2025;5:70000 PMCID:PMC12561301

[42] Ying SQ,Zhou ZK.Hepatocyte-derived tissue extracellular vesicles safeguard liver regeneration and support regenerative therapy.J Nanobiotechnology2024;22:521 PMCID:PMC11363633

[43] Ghallab A,Strängberg E.Inhibition of the renal apical sodium dependent bile acid transporter prevents cholemic nephropathy in mice with obstructive cholestasis.J Hepatol2024;80:268-81 PMCID:PMC10849134

[44] Wang M,Zhang Y.Toll-like receptor 4 signaling pathway mediates both liver and kidney injuries in mice with hepatorenal syndrome.Am J Physiol Gastrointest Liver Physiol2022;323:G461-76

[45] Liam-Or R,Walters A.Cellular uptake and in vivo distribution of mesenchymal-stem-cell-derived extracellular vesicles are protein corona dependent.Nat Nanotechnol2024;19:846-55 PMCID:PMC11186763

[46] Zhang K,Chen X.Renal endothelial cell-targeted extracellular vesicles protect the kidney from ischemic injury.Adv Sci2023;10:e2204626 PMCID:PMC9875634

[47] Mao J,Wu F.MSC-EVs transferring mitochondria and related components: a new hope for the treatment of kidney disease.Front Immunol2022;13:978571 PMCID:PMC9556818

[48] Jovic D,Wang D.A brief overview of global trends in MSC-based cell therapy.Stem Cell Rev Rep2022;18:1525-45 PMCID:PMC8958818

[49] Zaripova LN,Christmas SE.Mesenchymal stem cells in the pathogenesis and therapy of autoimmune and autoinflammatory diseases.Int J Mol Sci2023;24:16040 PMCID:PMC10671211

[50] Chen J,Jin Y.Mesenchymal stromal cell-mediated immune regulation: a promising remedy in the therapy of type 2 diabetes mellitus.Stem Cells2021;39:838-52

[51] Deptuła M,Skoniecka A,Pikuła M.Adipose-derived stromal cells for nonhealing wounds: emerging opportunities and challenges.Med Res Rev2021;41:2130-71 PMCID:PMC8247932

[52] Mathew SA,Cahill PA.Placental mesenchymal stromal cells as an alternative tool for therapeutic angiogenesis.Cell Mol Life Sci2020;77:253-65 PMCID:PMC11104823

[53] Kalluri R.The biology and function of extracellular vesicles in immune response and immunity.Immunity2024;57:1752-68 PMCID:PMC11401063

[54] Visnovitz T.Extracellular vesicles: biology and therapeutic applications.Int J Mol Sci2024;25:13034 PMCID:PMC11641679

[55] Lu W.Mesenchymal stromal cell therapy: progress to date and future outlook.Mol Ther2025;33:2679-88 PMCID:PMC12172195

[56] Porreca S,Frasca L.The role of CXCL4 in systemic sclerosis: DAMP, auto-antigen and biomarker.Int J Mol Sci2025;26:2421 PMCID:PMC11942444

[57] Chen R,Liu J,Tang D.DAMPs in the immunogenicity of cell death.Mol Cell2025;85:3874-89

[58] Qu B,Xie Y.Interleukin-17 A and diabetic kidney disease: emerging evidence on its pathogenic role and targeted modulation.Acta Diabetol2025;Epub ahead of print:

[59] Li N,Fuji H.Interleukin-17 in liver disease pathogenesis.Semin Liver Dis2021;41:507-15